JPH04506752A - チロトロピンレセプター活性を有するポリペプチド、このレセプターとポリペプチドとをコードする核酸、そしてこのようなペプチドの利用 - Google Patents
チロトロピンレセプター活性を有するポリペプチド、このレセプターとポリペプチドとをコードする核酸、そしてこのようなペプチドの利用Info
- Publication number
- JPH04506752A JPH04506752A JP3501671A JP50167191A JPH04506752A JP H04506752 A JPH04506752 A JP H04506752A JP 3501671 A JP3501671 A JP 3501671A JP 50167191 A JP50167191 A JP 50167191A JP H04506752 A JPH04506752 A JP H04506752A
- Authority
- JP
- Japan
- Prior art keywords
- tsh
- sequence
- receptor
- amino acid
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020003175 receptors Proteins 0.000 title claims description 121
- 102000005962 receptors Human genes 0.000 title claims description 120
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 83
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 77
- 229920001184 polypeptide Polymers 0.000 title claims description 73
- 230000000694 effects Effects 0.000 title claims description 33
- 150000007523 nucleic acids Chemical class 0.000 title claims description 14
- 108020004707 nucleic acids Proteins 0.000 title claims description 6
- 102000039446 nucleic acids Human genes 0.000 title claims description 6
- 102000015486 thyroid-stimulating hormone receptor activity proteins Human genes 0.000 title claims description 5
- 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 title claims description 5
- 108090000253 Thyrotropin Receptors Proteins 0.000 claims description 78
- 102000003911 Thyrotropin Receptors Human genes 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 125000000539 amino acid group Chemical group 0.000 claims description 25
- 239000012528 membrane Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 230000027455 binding Effects 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 238000012217 deletion Methods 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 239000012472 biological sample Substances 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 10
- 102000030621 adenylate cyclase Human genes 0.000 claims description 9
- 108060000200 adenylate cyclase Proteins 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 238000004445 quantitative analysis Methods 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims description 3
- 230000003491 cAMP production Effects 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 238000013115 immunohistochemical detection Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 108010002164 tyrosine receptor Proteins 0.000 claims description 2
- 241000277269 Oncorhynchus masou Species 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 241001522296 Erithacus rubecula Species 0.000 claims 1
- 101710108416 Robin Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 56
- 210000001685 thyroid gland Anatomy 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 23
- 241000282465 Canis Species 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 102000023108 LH Receptors Human genes 0.000 description 8
- 108010011942 LH Receptors Proteins 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 210000000287 oocyte Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 108091006027 G proteins Proteins 0.000 description 5
- 102000030782 GTP binding Human genes 0.000 description 5
- 108091000058 GTP-Binding Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 108010061174 Thyrotropin Proteins 0.000 description 5
- 102000011923 Thyrotropin Human genes 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 229960000874 thyrotropin Drugs 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000001748 thyrotropin Effects 0.000 description 4
- 102000008175 FSH Receptors Human genes 0.000 description 3
- 108010060374 FSH Receptors Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 101710095468 Cyclase Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028665 Myxoedema Diseases 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 208000003786 myxedema Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000011269 tar Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000209128 Bambusa Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108050005395 Glycoprotein hormone receptor Proteins 0.000 description 1
- 235000008612 Gnetum gnemon Nutrition 0.000 description 1
- 240000000018 Gnetum gnemon Species 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 101710132457 Protein A1 Proteins 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108010041420 microbial alkaline proteinase inhibitor Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- -1 muscarinic Chemical compound 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108010002205 phospholipase C1 Proteins 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102220275318 rs1270851643 Human genes 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 230000001971 thyroidal effect Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/854—Glands
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (17)
- 1.第11図に示したアミノ酸配列たはその配列の断片、または第11図に示さ れたアミノ酸残基のいずれかが置換または欠失されることによって、または追加 のアミノ酸残基を挿入されることによって前記配列から誘導されたアミノ酸配列 からなることを特徴とするチロトロピンレセプター活性を有するポリペプチド。
- 2.以下の一般式で表わされるアミノ酸配列を含むことを特徴とする請求の範囲 第1項記載のポリペプチド。 一般式:[X]n−〔y]m−〔Z〕p式中、n=0または1、m=0または1 、p=0または1で、かつこれらはn+m+P>0 の関係にあり、 また、x,y,zは以下のように定義され(ひとっのアミノ酸を−文字で表わし ており、またいずれかひとっの部位にある複数の文字は、その部位での与えられ たアミノ酸残基のうちのひとっの存在を示すものである)、x=MRPADLL QLVLLLDLPROL,PPHAAS y=免疫学的な特性を現わすのに必要な以下の配列からなる連続的なアミノ酸の 少なくとも最小な数であり、 【配列があります】 そして、【配列があります】 式中、アミノ酸配列【配列があります】は、独立的に存在または不存在であり、 また以下の意味を有しており、【配列があります】 IV または、この配列の少なくとも12の連続するアミノ酸残基であり、【配列があ ります】 または、この配列の少なくとも12の連続するアミノ酸残基であり、【配列があ ります】 または、この配列の少なくとも2の連続するアミノ酸残基であり、【配列があり ます】 または、この配列の少なくとも22の連続するアミノ酸残基であり、【配列があ ります】 または、この配列の少なくとも2の連続するアミノ酸残基であり、【配列があり ます】 または、この配列の少なくとも12の連続するアミノ酸残基であり、【配列があ ります】 または、この配列の少なくとも12の連続するアミノ酸残基であり、【配列があ ります】 または、この配列の少なくとも12の連続するアミノ酸残基であり、【配列があ ります】 または、この配列の少なくとも12の連続するアミノ酸残基であり、【配列があ ります】 または、この配列の少なくとも12の連続するアミノ酸残基あり、上記に特定さ れたアミノ酸のどれでもは置換または欠失が可能であることが理解される。また 、上記配列の外側に記載されたアミノ酸残基は挿入可能であり、チロトロピンレ セプター活性は保持されるものである。
- 3.“y”は少なくとも以下のサブ配列:Y1ないしY13から少なくとも一っ 選択されるものであることを特徴とする請求の範囲第1項記載のポリペプチド。 【配列があります】
- 4.前記ポリペプチドの一部分、例えばトランスメンブランドメインを形成する 部分は前記TSHレセブターに対してヘテロなものなので、前記ポリペプチドは 雑種ポリペプチドであることを特徴とする請求の範囲第1項ないし第3項のいず れかの項記載のポリペプチド。
- 5.第11図に示された配列からなることを特徴とする請求の範囲第1項記載の ポリペプチド。
- 6.請求の範囲第1項ないし第5項記載のポリペプチドをコードするヌクレオチ ド配列と、 少なくとも8個のヌクレオチドからなる配列を有する断片と、12個のヌクレオ チドからなる配列を有する断片と、そしてより好ましくは少なくとも16個のヌ クレオチドとからなる配列を有する断片とからなる前記配列の断片と、前記配列 または断片と相補的な関係にあるヌクレオチド配列。
- 7.前記配列は、第5図また第12図に示された配列を有するDNA配列、ある いは 8個のヌクレオチドからなる配列、12個のヌクレオチドからなる配列、そして より好ましくは少なくとも16個のヌクレオチドからなる配列を存する断片、あ るいは 前記配列または断片と相補的な関係にあるヌクレオチド配列であることを特徴と する請求の範囲第5項記載にもとづくヌクレオチド配列。
- 8.前記核酸が操作的に押入されたベクターによって形質転換された宿主細胞内 で前記ポリペプチドをコードする核酸の発現にもとづくことを特徴とする請求の 範囲第1項ないし第5項記数のポリペプチドの調製方法。
- 9.請求の範囲第1項ないし第5項のいず札か一項記載のポリペプチドをTSH または抗TSHレセブタ−抗体を含むと思われる生物学的試料と接触させると同 時に、あるいは連続して、標識TSHまたは標識抗TSHレセブタ−抗体と接触 させ、そして標識されたものと、未標識のものとの拮抗の後に、標識TSHまた は標識抗TSHレセブタ−抗体の結合量を測定することを特徴とする生物学的試 料に含まれるチロトロビン(TSH)または抗チロトロビンレセブタ−抗体(抗 TSHレセブター)の定量的分析方法。
- 10.請求の範囲第5項または第6項の核酸配列によって形質転換された細胞ま たはそのような細胞から調製された膜分画と、TSHまたは抗TSHレセブタ− 抗体を含むと考えられる生物学的試料とを接触させ、それらの細胞たは膜分画で の、アデニリルシクラーゼ活性を、例えばcAMP産生または放出を測定するこ とを特徴とする生物学的試料に含まれるチロトロビン(TSH)または抗チロト ロビンレセブタ−抗体(抗TSHレセブター)の定量的分析方法。
- 11.レセプターポリペプチドペプチドを発現する細胞または前記細胞の膜分画 を、TSHと同時に、あるいはTSHとの接触前に、生物学的試料と接触させ、 そしてせ接触させ、生物学的試料中に含まれる抗TSHレセブタ−抗体を阻害す ることによって、TSHによるアデニリルシクラーゼ活性効果の阻害を行なうこ とを特徴とする請求の範囲第10項記載の方法。
- 12.請求の範囲第1項ないし第5項記載のレセプターポリペプチドに対する多 クローン抗体またはモノクローン抗体。
- 13.請求の範囲第1項ないし第5項のいずれか一項記載にもとづくポリペプチ ドと、TSH源または抗TSHレセブタ−抗体との接触と、結合したものと遊離 しているものとの分離と、レセブター結合TSHまたは抗体の解離とからなるT SHまたは刺激および阻害抗体の精製方法。
- 14.生物学的試料を請求の範囲第12項記載にもとづく抗体と接触させること によって前記生物学的試料中に含まれるTSHレセブターの断片を定量的に検出 するための方法であって、もし必要ならば前記抗体を事前に標識し、請求の範囲 第1項ないし第5項のいずれか一項記載にもとづくポリペプチドと前記断片との 間の拮抗によって、あるいは結合標識抗体を非結合標識抗体から分離することよ って結合測定を行なうもので、前記ポリペプチドは、例えば1251で標識され ていること特徴とする方法。
- 15.請求の範囲第12項記載の抗体を用いることを特徴とする生物学的試料に 含まれるTSHレセブターの免疫組織化学的検出方法。
- 16.(a)上記したようにチロシンレセプター活性を有し、かつ固定化または 可溶化された形状にある本発明にもとづくポリベブテド;(b)以下に示す少な くともひとつの試薬:i)標識TSH、 ii)標識抗TSHレセブタ−抗体、そしてiii)アデニリルシクラーゼ活性 の測定に必要な試薬、を含むことを特徴とするTSHまたは抗TSHレセブタ− 抗体を検出するためのキット。
- 17.前記ポリペプチドは、前記ポリペプチドをコードするヌクレオチド配列に よって事前に操作的に形質転換きれた細胞に存在し、必然的に前記細胞の膜に置 かれたかたちで、あるいは前記細胞の可溶化された膜のかたちで、存在すること を特徴とする請求の範囲第16項記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP89403493A EP0433509B1 (en) | 1989-12-14 | 1989-12-14 | Polypeptides having thyrotropin receptor activity, nucleic acid sequences coding for such receptors and polypeptides, and applications of these polypeptides |
EP89403493,3 | 1989-12-14 | ||
PCT/EP1990/002154 WO1991009121A2 (en) | 1989-12-14 | 1990-12-12 | Polypeptides having thyrotropin-receptor activity, nucleic acid sequences coding for such receptors and polypeptides, and applications of these polypeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04506752A true JPH04506752A (ja) | 1992-11-26 |
JP3090682B2 JP3090682B2 (ja) | 2000-09-25 |
Family
ID=8203015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP03501671A Expired - Lifetime JP3090682B2 (ja) | 1989-12-14 | 1990-12-12 | チロトロピンレセプター活性を有するポリペプチド、このレセプターとポリペプチドとをコードする核酸、そしてこのようなペプチドの利用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6228597B1 (ja) |
EP (2) | EP0433509B1 (ja) |
JP (1) | JP3090682B2 (ja) |
AT (2) | ATE145240T1 (ja) |
AU (1) | AU641209B2 (ja) |
CA (1) | CA2046917C (ja) |
DE (2) | DE68927461T2 (ja) |
DK (1) | DK0458940T3 (ja) |
ES (2) | ES2092998T3 (ja) |
WO (1) | WO1991009121A2 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6261800B1 (en) | 1989-05-05 | 2001-07-17 | Genentech, Inc. | Luteinizing hormone/choriogonadotropin (LH/CG) receptor |
ES2180550T3 (es) * | 1989-05-05 | 2003-02-16 | Genentech Inc | Moleculas receptoras de la hormona de glycoproteina. |
US5614363A (en) * | 1990-01-25 | 1997-03-25 | New England Medical Center Hospitals, Inc. | TSH receptor |
JP3181582B2 (ja) * | 1989-09-08 | 2001-07-03 | ニューイングランド・メディカル・センター・ホスピタルズ・インコーポレーテッド | Tsh受容体 |
WO1991009137A1 (en) * | 1989-12-20 | 1991-06-27 | Basil Rapoport | Recombinant thyrotropin receptor |
EP0482598A3 (en) * | 1990-10-24 | 1993-05-19 | Ishihara Sangyo Kaisha, Ltd. | Peptide analog of human tsh receptor affective against autoimmune hyperthyroidism |
EP0719858A3 (en) * | 1994-12-27 | 1997-12-29 | Tosoh Corporation | Myeloma cell line expressing recombinant human thyroid stimulating hormone receptor |
DE19645729C1 (de) * | 1996-11-06 | 1998-06-04 | Brahms Diagnostica Gmbh | Rezeptorbindungsassay, für den Rezeptorbindungsassay geeigneter rekombinanter Fusionsrezeptor, Vektor zu dessen Herstellung sowie Reagenziensatz für die Durchführung des Rezeptorbindungsassays |
DE19728991A1 (de) * | 1996-11-06 | 1999-02-11 | Brahms Diagnostica Gmbh | Rezeptorbindungsassay, für den Rezeptorbindungsassay geeigneter rekombinanter Fusionsrezeptor, Vektor zu dessen Herstellung sowie Reagenziensatz für die Durchführung des Rezeptorbindungsassays |
DE19651093C2 (de) * | 1996-12-09 | 1999-06-10 | Brahms Diagnostica Gmbh | Rezeptorbindungsassay zum Nachweis von TSH-Rezeptor-Autoantikörpern sowie Reagenziensatz für die Durchführung eines solchen Rezeptorbindungsassays |
DE19801154A1 (de) * | 1998-01-14 | 1999-07-15 | Brahms Diagnostica Gmbh | Verfahren zur Herstellung von gereinigten und gegebenenfalls markierten TSH-Rezeptor-Präparaten, neue radioiodierte TSH-Rezeptor-Präparate, und die Verwendung derartiger Präparate in Diagnostik und Therapie |
DE19907094C1 (de) | 1999-02-19 | 2000-04-13 | Brahms Diagnostica Gmbh | Verwendung von blockierenden Anti-TSH-Rezeptor-Antikörpern bei der Therapie von Hyperthyreosen sowie monoklonale Antikörper für eine solche Verwendung |
ATE302415T1 (de) * | 1999-10-12 | 2005-09-15 | Ulrich Loos | Verfahren zur bestimmung von autoantikörpern gegen den tsh-rezeptor |
WO2002034042A2 (en) * | 2000-10-26 | 2002-05-02 | Deltagen, Inc. | Knockout mice thyroid stimulating hormone receptor (tsh-r) gene |
GB2376016A (en) * | 2001-05-30 | 2002-12-04 | Nadir R Farid | Thyrotropin receptor (TSHR) domain cleavage catalysed by the metalloprotease ADAM 10 |
EP2383290B1 (en) * | 2001-08-23 | 2019-05-08 | Rsr Limited | Epitope regions of a thyrotropin (tsh) receptor, uses thereof and antibodies thereto |
WO2004048415A1 (de) * | 2002-11-26 | 2004-06-10 | B.R.A.H.M.S Aktiengesellschaft | Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern |
ES2461593T3 (es) | 2005-06-24 | 2014-05-20 | Bayer Cropscience Nv | Métodos para alterar la reactividad de paredes de células vegetales |
US8097699B2 (en) | 2006-08-30 | 2012-01-17 | Rsr Limited | Crystal structure of thyroid stimulating hormone receptor |
WO2008091981A2 (en) * | 2007-01-25 | 2008-07-31 | Cedars-Sinai Medical Center | Monoclonal antibody that suppresses thyrotropin receptor constitutive activity |
GB201314052D0 (en) | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4448764A (en) * | 1982-07-06 | 1984-05-15 | Pierce Chemical Company | Direct-acting iodinating reagent |
HU195580B (en) * | 1985-11-20 | 1988-05-30 | Gyula Bako | Method for detecting antibodies for thyroid antigens |
DE3609271A1 (de) * | 1986-03-19 | 1987-09-24 | Boehringer Mannheim Gmbh | Verfahren und reagenz zum nachweis von autoimmunerkrankungen, arzneimittel zur behandlung von autoimmunerkrankungen sowie hierzu geeignete antiparatypische antikoerper |
US5144007A (en) * | 1988-11-03 | 1992-09-01 | La Jolla Cancer Research Foundation | Thyroid hormone receptor |
JP3181582B2 (ja) * | 1989-09-08 | 2001-07-03 | ニューイングランド・メディカル・センター・ホスピタルズ・インコーポレーテッド | Tsh受容体 |
US5614363A (en) | 1990-01-25 | 1997-03-25 | New England Medical Center Hospitals, Inc. | TSH receptor |
WO1991009137A1 (en) * | 1989-12-20 | 1991-06-27 | Basil Rapoport | Recombinant thyrotropin receptor |
-
1989
- 1989-12-14 ES ES89403493T patent/ES2092998T3/es not_active Expired - Lifetime
- 1989-12-14 DE DE68927461T patent/DE68927461T2/de not_active Expired - Lifetime
- 1989-12-14 EP EP89403493A patent/EP0433509B1/en not_active Expired - Lifetime
- 1989-12-14 AT AT89403493T patent/ATE145240T1/de not_active IP Right Cessation
-
1990
- 1990-12-12 AU AU70386/91A patent/AU641209B2/en not_active Expired
- 1990-12-12 ES ES91901286T patent/ES2091317T3/es not_active Expired - Lifetime
- 1990-12-12 JP JP03501671A patent/JP3090682B2/ja not_active Expired - Lifetime
- 1990-12-12 EP EP91901286A patent/EP0458940B1/en not_active Expired - Lifetime
- 1990-12-12 DE DE69028695T patent/DE69028695T2/de not_active Expired - Lifetime
- 1990-12-12 DK DK91901286.4T patent/DK0458940T3/da active
- 1990-12-12 US US07/741,453 patent/US6228597B1/en not_active Expired - Lifetime
- 1990-12-12 AT AT91901286T patent/ATE143375T1/de not_active IP Right Cessation
- 1990-12-12 CA CA002046917A patent/CA2046917C/en not_active Expired - Lifetime
- 1990-12-12 WO PCT/EP1990/002154 patent/WO1991009121A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
DK0458940T3 (da) | 1996-11-11 |
EP0433509B1 (en) | 1996-11-13 |
AU641209B2 (en) | 1993-09-16 |
ATE145240T1 (de) | 1996-11-15 |
WO1991009121A3 (en) | 1991-09-19 |
ATE143375T1 (de) | 1996-10-15 |
AU7038691A (en) | 1991-07-18 |
EP0458940A1 (en) | 1991-12-04 |
DE68927461D1 (de) | 1996-12-19 |
DE68927461T2 (de) | 1997-03-20 |
ES2091317T3 (es) | 1996-11-01 |
CA2046917C (en) | 2003-07-01 |
ES2092998T3 (es) | 1996-12-16 |
DE69028695T2 (de) | 1997-02-20 |
EP0433509A2 (en) | 1991-06-26 |
EP0433509A3 (en) | 1991-07-24 |
CA2046917A1 (en) | 1991-06-15 |
EP0458940B1 (en) | 1996-09-25 |
US6228597B1 (en) | 2001-05-08 |
JP3090682B2 (ja) | 2000-09-25 |
WO1991009121A2 (en) | 1991-06-27 |
DE69028695D1 (de) | 1996-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH04506752A (ja) | チロトロピンレセプター活性を有するポリペプチド、このレセプターとポリペプチドとをコードする核酸、そしてこのようなペプチドの利用 | |
EP0574579B1 (en) | Dna encoding a human 5-ht 1f receptor and uses thereof | |
JPH09509314A (ja) | 神経ペプチドy/ペプチドyy(y2)受容体をコードした核酸、及び該核酸の使用 | |
JP2002521055A (ja) | 98個のヒト分泌タンパク質 | |
JPH10510709A (ja) | 摂食行動を変える方法、該方法に有用な化合物、および視床下部の異型神経ペプチドy/ペプチドyy受容体(y5)をコードするdna | |
JP2002533058A (ja) | 97個のヒト分泌タンパク質 | |
JP2004533840A (ja) | ファージディスプレイによるpdzドメインリガンド | |
JPH09511127A (ja) | ヒト神経ペプチドy/ペプチドyy/膵臓ポリペプチド受容体(y4)をコードしたdna、及び該dnaの使用 | |
JP2001515349A (ja) | Tm4sfヒト腫瘍関連抗原 | |
JP2002112772A (ja) | 新規ポリペプチドおよびそのdna | |
JP2002514882A (ja) | グリシン輸送体をコードするdnaおよびその使用 | |
JP2001526535A (ja) | ヒトケルベロスタンパク質 | |
CA2482810C (en) | Teneurin c-terminal associated peptides (tcap) and methods and uses thereof | |
JPH11507513A (ja) | C5a様7膜貫通受容体 | |
WO2006068326A1 (ja) | 新規ポリペプチドおよびその用途 | |
US6849728B1 (en) | GLUT10: a glucose transporter in the type 2 diabetes linked region of chromosome 20Q12-13.1 | |
US20050003477A1 (en) | Pacemaker ion channel proteins and uses thereof | |
KR100971270B1 (ko) | 이피에프 수용체 에세이, 화합물 및 치료학적 조성물 | |
WO2001081401A1 (fr) | Nouvelles collectines | |
JP2002514078A (ja) | Fthma−070関連蛋白質ファミリーおよびt85関連蛋白質ファミリーの新規分子ならびにそれらの使用 | |
JPH11501817A (ja) | ヒト臍静脈内皮細胞で発現されるヒアルロン酸レセプタ | |
WO2001046415A1 (fr) | Polypeptides de type tachykinine et utilisation associee | |
JP2005510214A (ja) | 肥満と2型糖尿病に関連のある差異的に発現する遺伝子 | |
EP1179540A1 (en) | Novel polypeptide | |
AU782897B2 (en) | Compounds related to or derived from GFRalpha4 and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080721 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090721 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090721 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100721 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100721 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110721 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110721 Year of fee payment: 11 |